The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of Participants With Adverse Reaction (AR)
Timeframe: For 28 days after the booster (4th) dose
Proportion of Participants With Serious Adverse Reaction (SAR)
Timeframe: For 28 days after the booster (4th) dose
Proportion of Participants With Reactogenicity (≥ Grade 1) in Those Who Are Younger Than 2 Years of Age
Timeframe: Within 7 days after the date of the booster (4th) dose
Proportion of Participants With Reactogenicity (≥ Grade 1) in Those Who Are Aged 2 Years or Older
Timeframe: Within 7 days after the date of the booster (4th) dose